Skip to main content

Table 6 (abstract P430). Laboratory features and treatment modalities of the patients

From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three

  A B1 B2 C1 C2
CH50 35% (70-140) 29% (40-130) 27% (40-130) <3 U/ml (30-75) <3 U/ml (30-75)
C1q <6 mg/L (118-238) 126% (70-130) 150% (70-130) Not evaluated 25 mg/dl (12-22)
C2 Not evaluated Not evaluated 40 mg/L (14-25) Not evaluated 3.1 mg/dl (1.13)
C3 175 mg/dl (90-180) 104 mg/dl (90-180) 152 mg/dl (90-180) 119 mg/dl (90-180) 95 mg/dl (90-180)
C4 37 mg/dl (10-40) 31 mg/dl (10-40) 38 mg/L (10-40) 30.4 mg/dl (10-40) 26mg/dl (10-40)
Prior treatment Steroid Steroid Steroid Steroid No treatment
Azathioprine Methotrexate Methotrexate Azathioprine
Hydroxychloroquine Hydroxychloroquine Hydroxychloroquine Hydroxychloroquine
Present treatment Hydroxychloroquine Hydroxychloroquine Hydroxychloroquine Hydroxychloroquine Hydroxychloroquine
FFP FFP FFP FFP FFP
Time of FFP treatment 37 months 28 months 30 months 7 months 7 months
Frequency of FFP 3 weekly 4 weekly 3 weekly Once a week Once a week